I/D ACE gene polymorphism in survival of leukemia patients - Hypothesis and pilot study

Medical Hypotheses

Volumn 61, Issue 1, 2003, Pages 80-85

  Hajek, Dobroslav ^a   Tomiska, Miroslav ^b   Krahulcova, Eva ^b   Druckmuller, Miloslav ^c   Florianova, Michaela ^a   Izakovicova Holla, Lydie ^a   Vacha, Jiri ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; BLOOD GROUP ABO SYSTEM; BONE MARROW; CANCER MORTALITY; CANCER SURVIVAL; CELL VOLUME; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HUMAN; LEUKEMIA; MALE; PILOT STUDY; PRIORITY JOURNAL; REVIEW;

EID: 0038677989     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00122-1     Document Type: Review

References (46)

1. Montgomery H., Clarkson P., Barnard M. et al. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 1999; 353: 541-545.
2. Hajek D., Kubesova H., Vyzula R. et al. Bone marrow as multidimensional orbit oscillator after autologous bone marrow transplantation. Stem Cells 1999; 17: 25-30.
3. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
4. Cidl K., Strelcova L., Znojil V., Vacha J. Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Exp Hematol 1996; 24: 790-794.
5. Vasku A., Soucek M., Znojil V. et al. Angiotensin I-converting enzyme and angiotensinogen gene interaction and prediction of essential hypertension. Kidney Int 1998; 53: 1479-1482.
6. Staessen J. A., Wang J. G., Ginocchio G. et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997; 15: 1579-1592.
7. Missouris C. G., Barley J., Jeffery S., Carter N. D., Singer D. R., MacGregor G. A. Genetic risk for renal artery stenosis: association with deletion polymorphism in angiotensin 1-converting enzyme gene. Kidney Int 1996; 49: 534-537.
8. Kario K., Matsuo T., Kobayashi H. et al. Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol 1998; 32: 444-450.
9. Fernandez-Llama P., Poch E., Oriola J. et al. Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998; 53: 1743-1747.
10. Celentano A., Mancini F. P., Crivaro M. et al. Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol 1999; 83: 1196-1200.
11. Arnett D. K., Borecki I. B., Ludwig E. H. et al. Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: the atherosclerosis risk in communities and the NHLBI family heart studies. Atherosclerosis 1998; 138: 111-116.
12. Fyhrquist F., Metsarinne K., Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens 1995; 9(Suppl 5): S19-S24.
13. Mazzolai L., Nussberger J., Aubert J. F. et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998; 31: 1324-1330.
14. Stock P., Liefeldt L., Paul M., Ganten D. Local renin-angiotensin systems in cardiovascular tissues: localization and functional role. Cardiology 1995; 86(Suppl 1): 2-8.
15. Lindpaintner K., Ganten D. Tissue renin-angiotensin systems and their modulation: the heart as a paradigm for new aspects of converting enzyme inhibition. Cardiology 1991; 79(Suppl 1): 32-44.
16. Vasku A., Soucek M., Hajek D., Holla L., Znojil V., Vacha J. Asociation analysis of 24-h blood pressure records with I/D ACE gene polymorphism and ABO blood group system. Physiol Res 1999; 48: 99-104.
17. Vasku A., Soucek M., Znojil V. et al. Does angiotensin I-converting enzyme inhibitor therapy have an antiproliferative effect on blood-forming bone marrow? [letter]. Exp Hematol 1998; 26: 277-279.
18. Li J., Volkov L., Comte L., Herve P., Praloran V., Charbord P. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells. Exp Hematol 1997; 25: 140-146.
19. Rousseau-Plasse A., Lenfant M., Potier P. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site. Bioorg Med Chem 1996; 4: 1113-1119.
20. Haznedaroglu I. C., Tuncer S., Gursoy M. A local renin-angiotensin system in the bone marrow. Med Hypotheses 1996; 46: 507-510.
21. Rousseau-Plasse A., Wdzieczak-Bakala J., Lenfant M. et al. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo. Exp Hematol 1998; 26: 1074-1079.
22. Pospisil M., Sikulova J., Sevcik F. The fluctuation of urine electrolyte excretion and its relation to mortality of multiple irradiated mice. Z Ges Exp Med 1965; 139: 112-121.
23. Vacha J., Pospisil M. A contribution to the question of individual differences in the regulatory balance of the functions of organism. Life Sci 1967; 6: 2251-2259.
24. Pospisil M. Hormonal balance and radiation resistance of the mammalian organism. A speculative review. Agressologie 1977; 18: 73-81.
25. Hajek D. The clinical use of Na/K oscillations in urine. In: G. Guttenbrunner, G. Hildebrandt, R. Moog (eds). Chronobiology & Chronomedicine, Basic Research and Applications. Peter Lang: Frakfurt am Main, 1993: 386-389.
26. Hudeckova M., Hajek D., Dohnal K. Clinical aspects of regulatory pathology. Cesk Neurol Neurochir 1986; 49: 415-416.
27. Cornelissen G., Portela A., Halberg F., Bolliet V., Falcon J. Toward a chronome of superfused pike pineals: about-weekly (circaseptan) modulation of circadian melatonin release. In Vivo 1995; 9: 323-329.
28. Halberg F. The week in phylogeny and ontogeny: opportunities for oncology. In Vivo 1995; 9: 269-278.
29. Halberg F., Lakatua D., Lodeiro C. et al. Chronobiology, growth hormone and healthy and malignant growth. J Endocrinol Invest 1989; 12(Suppl 3): 41-47.
30. Focan C., Cornelissen G., Halberg F. Chronometaanalysis: circasemiseptan (3.5-day) pattern in mitotic activity of murine sarcoma after treatment with cyclophosphamide. In Vivo 1995; 9: 401-406.
31. Blank M., Cornelissen G., Halberg F. Circasemiseptan (about-half-weekly) and/or circaseptan (about-weekly) pattern in human mitotic activity? In Vivo 1995; 9: 391-394.
32. Hajek D., Simcikova B., Vorlicek J. Circaseptan rhythm restitution by means of timed high dose methyprednisolon - an improvement of cytostatic treatment response? J Interdiscipl Cycle Res 1993; 24: 342-344.
33. Hajek D., Vasku A., Simcikova B. The electrolyte concentration uctuations in urine after a single dose of methylprednisolone. Scripta Medica 1997; 70: 383-394.
34. Hajek D., Simcikova B. The effect of pulsed methylprednisolone on the fluctuations of electrolyte concentrations in urine [abstract]. Chronobiol Int 1996; 13(Suppl 1): 43.
35. Lloyd D., Lloyd A. L., Olsen L. F. The cell division cycle: a physiologically plausible dynamic model can exhibit chaotic solutions. BioSystems 1992; 27: 17-24.
36. Lloyd A. L., Lloyd D. Hypothesis: the central oscillator of the circadian clock is a controlled chaotic attractor. BioSystems 1993; 29: 77-85.
37. Schweisfurth H., Schmidt M., Brugger E., Maiwald L., Thiel H. Alterations of serum carboxypeptidases N and angiotensin-I-converting enzyme in malignant diseases. Clin Biochem 1985; 18: 242-246.
38. Cotter T. P., Kealy N. P., Duggan P. F., Curtain A., Bredin C. P. Elevated serum angiotensin converting enzyme levels in metastatic ovarian dysgerminoma. Respir Med 1997; 91: 237-239.
39. Reddy M. K., Baskaran K., Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995; 210: 221-226.
40. Lever A. F., Hole D. J., Gillis C. R. et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
41. Haznedaroglu I. C., Arici M., Buyukasik Y. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Med Hypotheses 2000; 54: 80-83.
42. Holla L., Vasku A., Soucek M., Krahulcova E., Hajek D., Znojil V. Angiotensin-converting enzyme gene polymorphism and blood groups of the ABO system in leukemias compared with controls and hypertensives. Scripta Medica (Brno) 1988; 71: 471-477.
43. Chisi J. E., Briscoe C. V., Ezan E., Genet R., Riches A. C., Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol 2001; 109: 563-570.
44. Rigat B., Hubert C., Corvol P., Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20: 1433.
45. Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A. et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29: 152-163.
46. Fenaux P. Myelodysplastic syndromes. Hematol Cell Ther 1996; 38: 363-380.